-
公开(公告)号：US20230192807A1
公开(公告)日：2023-06-22
申请号：US17925216
申请日：2021-05-14
IPC分类号： C07K14/725 , C07K14/705 , C07K16/28
CPC分类号： C07K14/7051 , C07K14/70517 , C07K16/2803 , C07K16/2893 , A61K2039/5156
摘要： The present invention encompasses methods for reducing the number of target cells in a subject, such as cancer cells. The methods include administration of genetically-modified human immune cells expressing a chimeric antigen receptor or exogenous T cell receptor, which have specificity for an antigen on the target cells. Administration of the genetically-modified immune cells is preceded by the administration of a tolerance regimen, followed by administration of a lymphodepletion regimen, to improve efficacy of the therapy and persistence of the cells in vivo.
-
公开(公告)号：US20230190780A1
公开(公告)日：2023-06-22
申请号：US17925277
申请日：2021-05-14
发明人： Christopher Ryan Heery , Daniel H. Fowler , Alan F. List , Aaron Martin , Daniel T. MacLeod , Derek Jantz
IPC分类号： A61K31/7056 , A61K31/675 , C07K16/28 , C07K14/725 , A61K31/436 , A61P35/00
CPC分类号： A61K31/7056 , A61K31/675 , C07K16/2893 , C07K14/7051 , A61K31/436 , A61P35/00 , A61K2039/545
摘要： The present invention encompasses methods for reducing the number of target cells in a subject, such as cancer cells. The methods include administration of genetically-modified human immune cells expressing a chimeric antigen receptor or exogenous T cell receptor, which have specificity for an antigen on the target cells Administration of the genetically-modified immune cells can be preceded by the administration of a lymphodepletion region and/or an immunosuppression regimen, to improve efficacy of the therapy and persistence of the cells in vivo.
-
搜索结果
2 条记录 (耗时 0.013 秒)
